{"id":75,"date":"2023-09-20T13:09:41","date_gmt":"2023-09-20T04:09:41","guid":{"rendered":"http:\/\/www.lifescience.shokubai.co.jp\/home\/our-team\/"},"modified":"2025-10-08T09:30:54","modified_gmt":"2025-10-08T00:30:54","slug":"our-team","status":"publish","type":"page","link":"https:\/\/www.lifescience.shokubai.co.jp\/en\/our-team\/","title":{"rendered":"Our Team"},"content":{"rendered":"\n
\n
\n
\n \"Who\n <\/div>\n

\n Who We Are\n <\/h2> \n <\/div>\n
\n

“Nippon Shokubai has a long-term approach. That is why we stand behind you as you help build the business.” <\/h3>\n
\n

\n These words were how a board member described the company to me in 2019, seven years after Nippon Shokubai had entered the life science sector.
Already, the life sciences have changed incredibly. Super-aging societies are accelerating, putting pressure on the development of new modalities such as regenerative medicine. It is in this environment that the Health & Medical Business Division of Nippon Shokubai built an oligonucleotide and peptide API synthesis facility in 2019. Since then, we have accelerated the establishment of our CDMO systems, and in 2021, we made our first shipment of GMP APIs.

\n\n In just 10 years, Nippon Shokubai, a leading synthetic chemical company, has established a mass production system of oligonucleotide and peptide APIs. There are two reasons for this success.
\n One is the attitude of nurturing the business patiently, as stated above. The other reason is the “insatiable curiosity, inquiring minds\u201d all our employees have. We entered this sector with limited knowledge or experience in drug discovery. However, we had confidence in our employees. I was surprised how quickly our business grew into a CDMO, built elaborate research facilities, and initiated active partnerships with academia and venture development companies.

\n\nUnderlying our rapid growth is our mission of “TechnoAmenity: Providing prosperity and comfort to people and society, with our unique technology”. It is our corporate culture to develop Amenity through the power of Techno \u30fc constantly using evolving technology to benefit people and society. \n\n

\n\nThe life sciences are testing human ingenuity for a better world. Nippon Shokubai is contributing to society with this goal in mind. As a team that “creates value through technology,\u201d we would be happy to work together as partners.\n <\/p>\n\n

\n \n \n \"\"\n <\/picture>\n

Shingo Horimoto, Ph.D.<\/p>\n

Director of Health & Medical Business Division<\/p>\n <\/div>\n\n <\/div>\n\n <\/div>\n<\/section>\n\n\n\n

\n
\n
\n \"Our\n <\/div>\n

\n Our Goal\n <\/h2> \n <\/div>\n
\n
\n
\n

Nippon Shokubai supports human health and medical care and contributes to the future of society by supplying oligonucleotide and peptide APIs.<\/h3>\n\n

\n Oligonucleotide and peptide APIs are a new modality that fill a gap caused by the limitations of low molecule and high molecule (antibody) drugs.
\n\nWe provide solutions in oligonucleotide and peptide medicines and DDS markets by having established a leading GMP system in Japan, unique technologies, and a one-stop shop service system from exploratory research to clinical trials, thereby contributing to therapeutic technologies in disease areas where treatment satisfaction is low.\n <\/p>\n <\/div>\n\n

\n \n \n \"\"\n <\/picture>\n <\/div>\n\n <\/div>\n\n <\/div>\n<\/section>\n\n\n\n
\n
\n
\n \"Our\n <\/div>\n

\n Approach\n <\/h2> \n <\/div>\n
\n
\n
\n \n \n \"\"\n <\/picture>\n

Providing a wide range of manufacturing<\/h3>\n\n

\n We have established a system suitable for exploratory research to clinical trials, which enables us to offer solutions ranging from small-scale synthesis for drug efficacy and toxicity evaluation in the drug discovery stage, to contract research on processes and testing methods for pilot manufacturing, and GMP-compliant API manufacturing for clinical trials.
\n\nAlso, we offer a variety of manufacturing scales ranging from a few \u00b5g in the exploratory research stage to 500 g in the late clinical stage. \n <\/p>\n <\/div>\n\n

\n \n \n \"\"\n <\/picture>\n

Active collaborations with promising venture companies and academia <\/h3>\n

\n Since forming a capital and business alliance with GlyTech, Inc. in 2015 to jointly advance manufacturing process development and clinical trials, we have actively expanded collaborations with leading domestic biotech ventures. In 2016, we entered into a capital alliance with TAK-Circulator Corporation, followed by the acquisition of Rena Therapeutics Inc. in 2019 and Lilac pharma Inc. in 2024.\n Through these and other diverse initiatives, we strive to advance pioneering research and the development of unique technologies.\n <\/p>\n <\/div>\n <\/div>\n\n <\/div>\n<\/section>\n\n\n\n

\n
\n
\n \"Members\"\n <\/div>\n

\n Members\n <\/h2>\n <\/div>\n
\n

Our experienced professionals work as a team for the success of your project.<\/h3>\n
\n

R&D (synthesis, analysis, DDS)<\/h4>\n